• 1
    Perry MC. The chemotherapy source book. 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 2001.
  • 2
    Perry MC, Yarbro JW. Toxicity of chemotherapy. Orlando, FL: Grune & Stratton, Inc., 1984.
  • 3
    Baquiran DC. Lippincott's cancer chemotherapy handbook. 2nd edition. Philadelphia: Lippincott Williams & Wilkins; 2001.
  • 4
    National Comprehensive Cancer Network. The complete library of NCCN oncology practice guidelines. Version 2000. Rockledge, PA: NCCN, 2000.
  • 5
    Abraham J, Allegra CJ. Bethesda handbook of clinical oncology. Philadelphia: Lippincott Williams & Wilkins; 2001.
  • 6
    Shifflett SL, Harvey RD III, McCune JS, Pfeiffer D, Lindley CM, Holdsworth M. Annotated guide to chemotherapeutic regimens 1999/2000. New York: McMahon Publishing Group, 1999.
  • 7
    Adami HO, Hunter D, Trichopoulos D. Textbook of cancer epidemiology. New York: Oxford University Press, 2002.
  • 8
    Hortobagyi GN, Frye D, Buzdar AU, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer. 1989; 63: 3745.
  • 9
    Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982; 96: 133139.
  • 10
    Speyer JL, Green MD, Dubin N, et al. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med. 1985; 78: 555563.
  • 11
    Bielack SS, Erttmann R, Winkler K, et al. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol. 1989; 25: 873882.
  • 12
    Seidman AD, Hochhauser D, Gollub M, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol. 1996; 14: 18771884.
  • 13
    Giordano SH, Booser DJ, Murray JL, et al. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res. 2002; 8: 33603368.
  • 14
    Rowinsky EK, Chaudhry V, Forastiere AA, et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol. 1993; 11: 20102020.
  • 15
    Reichman BS, Seidman AD, Crown JP, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 1993; 11: 19431951.
  • 16
    Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989; 7: 425432.
  • 17
    Ng JS, Cameron DA, Leonard RC. Infusional 5-fluorouracil in breast cancer. Cancer Treat Rev. 1994; 20: 357364.
  • 18
    Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993; 31: 732748.
  • 19
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40(8 Suppl ): 318.
  • 20
    RiesLAG, EisnerMP, KosaryCL, et al, editors. SEER cancer statistics review, 1975–2000,. Bethesda, MD: National Cancer Institute, 2003. Available from URL: [accessed December 15, 2003].
  • 21
    National Cancer Institute. The SEER program code manual. Revised edition. NIH Pub No. 94-1999. Bethesda, MD: National Cancer Institute, 1994.
  • 22
    Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40(Suppl): IV55IV61.
  • 23
    Du XL, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol. 2001; 19: 14551461.
  • 24
    Du XL, Goodwin JS. Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996. Cancer. 2001; 92: 730737.
  • 25
    U.S. Public Health Services. International Classification of Diseases. 9th revision, clinical modification. 5th edition. Los Angeles: PMIC, 1996.
  • 26
    American Medical Association. Physicians' current procedural terminology–CPT 2000. Chicago: American Medical Association, 2000.
  • 27
    Health Care Financing Administration. HCFA Common Procedure Coding System (HCPCS): National Level II Medicare Codes. Los Angeles: Practice Management Information Corporation, 2000.
  • 28
    National Cancer Institute. SEER-Medicare linked databases. Appendix for SEER-Medicare 2/ 2003 claims files. Available from URL:[accessed January 20, 2005].
  • 29
    Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 12581267.
  • 30
    National Cancer Institute. SEER-Medicare calculation of comorbidity weights. Available from URL: [accessed July 26, 2004].
  • 31
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373383.
  • 32
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613619.
  • 33
    Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993; 46: 10751079.
  • 34
    Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS system. Cary, NC: SAS Institute Inc., 1997.
  • 35
    Du XL, Key CR, Dickie L, Darling R, Geraci JM, Zhang D. External validation of Medicare claims for breast cancer chemotherapy compared to medical chart reviews. Med Care. In press.
  • 36
    Du XL, Jones DV, Zhang D. Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women. J Gerontol (A Biol Sci Med Sci). In press.
  • 37
    Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest. 2000; 117: 12391246.
  • 38
    Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol. 2001; 19: 10641070.
  • 39
    Schrag D, Cramer LD, Bach PB, et al. Age and adjuvant chemotherapy use after surgery for Stage III colon cancer. J Natl Cancer Inst. 2001; 93: 850857.
  • 40
    Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results–Medicare. J Clin Oncol. 2001; 19: 37123718.
  • 41
    Sundararajan V, Grann VR, Jacobson JS, Ahsan H, Neugut AI. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer J. 2001; 7: 213218.
  • 42
    Lamont EB, Lauderdale DS, Schilsky RL, Christakis NA. Construct validity of Medicare chemotherapy claims: the case of 5FU. Med Care. 2002; 40: 201211.
  • 43
    Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002; 20: 39994005.
  • 44
    Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol. 2002; 20: 17861792.
  • 45
    Sundararajan V, Hershman D, Grann VR, Jacobson JS, Neugut AI. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol. 2002; 20: 173178.
  • 46
    Sundararajan V, Mitra N, Jacobson JS, et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med. 2002; 136: 349357.
  • 47
    Neugut AI, Fleischauer AT, Sundararajan V, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol. 2002; 20: 26432650.
  • 48
    Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with Stage III colon cancer. J Clin Oncol. 2002; 20: 39923998.
  • 49
    Delea TE, Vera-Llonch M, Edelsberg JS, et al. The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer. Value Health. 2002; 5: 3543.
  • 50
    Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002; 20: 46364642.